About us

Welcome to our website, where we are dedicated to providing comprehensive solutions for the introduction, localization, and legalization of medical drugs.

At PHARMAPARK, we understand the complexities and challenges faced by individuals and organizations in navigating the landscape of medical drugs. Our team is here to support you throughout the entire process, offering expertise and guidance to solve a wide range of tasks and issues.

As one of the leading players in the biopharmaceutical industry in Russia, PHARMAPARK’s development strategy is centered around the creation and production of high-quality medications through biotechnology. We are committed to bringing both generic and original (brand name) medicines to the market, ensuring access to effective treatments for a wide range of health conditions.

We take immense pride in the quality and efficacy of our products, which are the result of rigorous research, development, and testing. Our commitment to excellence extends beyond borders, as our PHARMAPARK developments are protected by international and Russian patents. This ensures the integrity of our intellectual property and reinforces our position as a trusted and respected industry leader.

At PHARMAPARK our mission is to ensure that every individual facing debilitating diseases such as breast cancer, kidney cancer, lung cancer, colorectal cancer, hepatitis B and C, nephrology, anemia, nephroid tumors, psoriasis, rheumatoid arthritis, spondylitis, and paroxysmal nocturnal hemoglobinuria has access to the most effective and safe drugs available to combat their conditions.

We are driven by a relentless commitment to research, development, testing, and improvement, drawing upon the expertise and experience of leading global institutions and companies. Our aim is to create advanced biological drugs and cutting-edge technologies for mass production within Russia.

By harnessing the power of innovation and collaboration, we serve our shareholders, investors, partners, and, most importantly, our clients, who trust in the dedication and efforts of the entire PHARMAPARK team. Together, we save lives and contribute significantly to advancing the level of healthcare in our country, enhancing the quality of life for each patient.

Every day, we strive to bring new and effective drugs to the Russian Federation market, ensuring accessibility in every city and region. Our unwavering commitment drives us forward as we work tirelessly to make a positive impact on the lives of individuals and transform the healthcare landscape in Russia.
Join us in our mission as we combine expertise, compassion, and determination to empower patients, foster medical advancements, and create a healthier future for all.

2001

Company was founded

2003

Launch of the production complex on area of 2,500 m2

2004

First production line (prokaryotic) is prepared for the production of the first batch

2005

Obtained GMP certificate

2005

Registered the first product (interferon substance)

2005

Launch of the second production line (eukaryotic)

2006

Start of production of the first finished dosage form (Altevir)

2011

Signing of the cooperation agreement with Center of Genetic Engineering and Biotechnology of Cuba

2012

Opening of R&D center on area of 1000 sq m

2012

First product registered (Interferon substance)

2013

Launch of an additional production plant on area of 1000 sq m

2013

Walvax cooperation agreement signed

2015

Monoclonal Antibodies production line prepared and launched

2021

Beginning of cooperation with BIO-THERA (China) on localization and registration of medical drugs: GOLIMUMAB and USTEKINUMAB

2020

Participation in the development of a scalable industrial technology for the production of the Sputnik V vaccine

2019

Cooperation agreement signed with Prestige Biopharma (South Korea)

2018

Mabxience S.A. signed an agreement on localization of Rituximab

2001

2005

2012

2016

2023

2006

Start of production of the first finished dosage form (Altevir)

2011

Signing of the cooperation agreement with Center of Genetic Engineering and Biotechnology of Cuba

2005

Obtained GMP certificate

2005

Registered the first product (interferon substance)

2005

Launch of the second production line (eukaryotic)

2018

Mabxience S.A. signed an agreement on localization of Rituximab

2019

Cooperation agreement signed with Prestige Biopharma (South Korea)

2020

Participation in the development of a scalable industrial technology for the production of the Sputnik V vaccine

2021

Beginning of cooperation with BIO-THERA (China) on localization and registration of medical drugs: GOLIMUMAB and USTEKINUMAB

2022

Registration of OncoTarget's manufacturing site

2023

Start of collaboration with
Altos Biologics (Korea) for localization and
registration of Golimumab and Ustekinumab

2024

Start of collaboration with
BIO-THERA (China) for localization and
registration of Secukinumab

2012

Opening of R&D center on area of 1000 sq m

2012

First product registered (Interferon substance)

2013

Launch of an additional production plant on area of 1000 sq m

2013

Walvax cooperation agreement signed

2015

Monoclonal Antibodies production line prepared and launched

2001

2005

2012

2019

2024

2001

Company was founded

2003

Launch of the production complex on area of 2,500 m2

2004

First production line (prokaryotic) is prepared for the production of the first batch

Our services

Our highly experienced team is thrilled to provide the following services

R&D - Research and Development

At PHARMAPARK, we offer a comprehensive range of services that encompass the full cycle of development for biological medicines.

Registration (Legalization)

Production

Organization and launch of scalable serial production for various forms of medical products:

Marketing and Sales

Development of packaging, promotion and sale of registered drugs. Participation in tenders and public procurement.

Pipeline

Pipeline

OUR TEAM

At PHARMAPARK, we firmly believe that our greatest resource is people - our employees, our team.

They are the driving force behind our success, passionately committed to achieving our goals and objectives on a daily basis. Together, we constantly evolve, develop, and grow alongside the company.

Our management team comprises seasoned professionals with a wealth of experience ranging from 10 to 25 years in the field. Their expertise and in-depth knowledge enable us to tackle any challenge in the development, production, and distribution of biological preparations and substances.

Join us on our journey as we continue to build a dynamic and talented team focused on making a meaningful impact in the biopharmaceutical industry. Together, we will drive innovation, advance healthcare, and shape a better future for all.

Our Facilities

Own production facilities, warehouse complex and research center

Production lines are located at a specialized modern building with a total area of 3,600 thousand square meters.

This facility is used for pilot and industrial production of substances. Production capacity is formed by two hardware-technological lines that are capable of creating genetically engineered therapeutic proteins, cytokines and monoclonal antibodies. The first line consists of a eukaryotic cultivation section and two protein purification sections, the second line consists of a prokaryotic cultivation section and a protein purification section.

Since 2012, research on pharmaceutical development has been carried out by the Research and Development Center

The division carries out a full cycle of immunobiological drugs development (active pharmaceutical ingredients and finished dosage forms) based on recombinant proteins, including chemically modified ones. Development scope includes all stages of research.

The R&D Center consists of the Project Management Department, the Prokaryote Culture Laboratory, the Cell Engineering Department, the Biochemistry Laboratory, the Finished Pharmaceutical Products Development Group, the Analytical Methods Development and Transfer Department, and the Process Scaling and Validation Department.

PHARMAPARK’s own warehouse complex is located in close proximity to the production line.

The warehouse is equipped with a modern system of storage for finished medical products and substances along with consumables, packaging material and other necessary provision, movement and shipment of it in compliance with all state standards and regulations.

Companies cooperating with us:

Our Partners

We are proud to showcase our trusted relationships with some of the world's leading companies

With our successful experience and impeccable reputation in the biotechnology market, we offer you the opportunity to choose a reliable, predictable, and efficient partner for joint projects in the development, legalization, production, and sale of medicinal substances and drugs on the Russian market.